Altimmune, Inc.'s pemvidutide shows promising results in MASH resolution and weight loss, paving the way for phase 3 trials.

Altimmune shares cratered more than 50% on Thursday after its experimental obesity drug did not significantly improve liver ...

Madrigal has set a list price of the Rezdiffra of $47,400 per year, ahead of any discounts or rebates, which lies within the $39,600 to $50,100 range that the influential Institute for Clinical ...